Zurueck zur Suche

Reporte zur Charge 5BC7N

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

8Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 2 NV 1 AZ 1 TX 1 KS 1 FL 1 IL 1

VAERS 1518850

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

schwer
Staat
CA
Alter
0,3
Geschlecht
M
Eingang
01.08.2021
Impfdatum
29.07.2021
Beginn
30.07.2021
Tage bis Beginn
1,0
Dosis
2
Route/Site
PO / MO
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
CSF test normal Febrile convulsion Laboratory test normal

Symptomtext

Complex febrile seizure, onset 7/30. Two brief episodes on 7/30, prompting hospitalization 7/30-7/31.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Febrile convulsion
Hospital-Tage
-
Labordaten
Negative workup for sepsis and meningitis. Normal CSF studies (cellular and chemistry).
Aktuelle Erkrankungen
parainfluenza virus infection
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1525645

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

mild
Staat
CA
Alter
0,2
Geschlecht
F
Eingang
04.08.2021
Impfdatum
12.07.2021
Beginn
17.07.2021
Tage bis Beginn
5,0
Dosis
1
Route/Site
PO / MO
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Abdominal distension Haematochezia Occult blood positive Vomiting

Symptomtext

blood in stool, Dark red/gelatenous No pain/vomiting/bloating Resolved after 2 days.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Vomiting
Hospital-Tage
-
Labordaten
Fecal occult blood test - positive
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2355784

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

gering
Staat
NV
Alter
0,2
Geschlecht
M
Eingang
03.07.2022
Impfdatum
-
Beginn
22.06.2022
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

administered using two different batches; administered using two different batches; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 2-month-old male patient who received Rota (Rotarix lyophilized formulation) (batch number M4AR7, expiry date 6th July 2023) and (batch number 5BC7N, expiry date 11th July 2022) for prophylaxis. Co-suspect products included rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis. On 22nd June 2022, the patient received Rotarix lyophilized formulation. On an unknown date, the dose was an unknown dose. On 22nd June 2022, the patient started Rotarix Oral Applicator Device. On 22nd June 2022, unknown after receiving Rotarix lyophilized formulation and Rotarix Oral Applicator Device, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-June-2022 Reporter's comment: A nurse reported that the Rotarix vaccine was administered to a patient using an approved diluent from a batch with a powder of another batch of Rotarix. The reporter consented to follow-up. Additional supportive information: The patient received the Rotarix vaccine which was reconstituted using two different batches of Rotarix vaccine, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1703488

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge 5BC7N

gering
Staat
AZ
Alter
0,1
Geschlecht
U
Eingang
16.09.2021
Impfdatum
27.08.2021
Beginn
27.08.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

only the diluant was given; only the diluant was given; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 1-month-old patient who received DTPa (Reduced antigen) (Boostrix) (batch number 5BC7N, expiry date 11th July 2022) for prophylaxis. On 27th August 2021, the patient received Boostrix. On 27th August 2021, unknown after receiving Boostrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional information was provided as follows: The reporter stated that only the diluant was given for a Boostrix vaccine to a child, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter consented to follow up. The health care professional office gave permission to contact them. This case was linked with US2021192895, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021192895:same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1449395

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

gering
Staat
TX
Alter
0,2
Geschlecht
F
Eingang
06.07.2021
Impfdatum
24.06.2021
Beginn
24.06.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

Patient received a 1st dose of Hiberix, Pediarix, and Rotarix on 02Jun2021 and received a 2nd dose of Hiberix, Pediarix, and Rotarix on24Jun2021; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 2-month-old female patient who received Hib (Hiberix) (batch number UJ437AB, expiry date 3rd May 2022) for prophylaxis. Co-suspect products included DTPa-HBV-IPV (Pediarix) (batch number AZ472, expiry date 28th November 2022) for prophylaxis, dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis, Rota (Rotarix lyophilized formulation) (batch number 5BC7N, expiry date 11th July 2022) for prophylaxis and rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis. Concomitant products included Hib (Hiberix), DTPa-HBV-IPV (Pediarix) and Rota (Rotarix lyophilized formulation). On 24th June 2021, the patient received the 2nd dose of Hiberix, the 2nd dose of Pediarix, Pediarix Pre-Filled Syringe Device, the 2nd dose of Rotarix lyophilized formulation and Rotarix Oral Applicator Device. On 24th June 2021, unknown after receiving Hiberix, Pediarix, Pediarix Pre-Filled Syringe Device, Rotarix lyophilized formulation and Rotarix Oral Applicator Device and an unknown time after receiving Hiberix, Pediarix and Rotarix lyophilized formulation, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details provided were as follows: A medical assistant had reported that a patient received a 1st dose of Hiberix, Pediarix, and Rotarix on 02 June 2021 and received a 2nd dose of Hiberix, Pediarix, and Rotarix earlier than the recomended interval, which led to drug administration interval too short. No symptoms were reported. Reporter consented to follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1424080

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

gering
Staat
KS
Alter
0,2
Geschlecht
M
Eingang
24.06.2021
Impfdatum
21.06.2021
Beginn
22.06.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
PO / MO
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Haematochezia

Symptomtext

Bloody stools x24 hours. No intervention, self resolved. No fever, vomiting or feeding difficulties.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Haematochezia
Hospital-Tage
-
Labordaten
NA
Aktuelle Erkrankungen
Fussiness associated with gas.
Vorgeschichte
None
Andere Medikamente
None
Allergien
NA
Vorherige Impfungen
-

VAERS 1367814

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

gering
Staat
FL
Alter
0,3
Geschlecht
M
Eingang
02.06.2021
Impfdatum
02.06.2021
Beginn
02.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Unevaluable event

Symptomtext

Pts mom to monitor pt and injection site and will contact office if any concerns.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
Dermatitis 6-1-2021; RSV/Bronchiolitis 5-2021
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 1301953

GLAXOSMITHKLINE BIOLOGICALS · ROTAVIRUS (ROTARIX) · Charge 5BC7N

gering
Staat
IL
Alter
0,3
Geschlecht
M
Eingang
10.05.2021
Impfdatum
06.05.2021
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
PO / MO
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

Pediarix and Rotarix / Below temperature exursion; This case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a 4-month-old male patient who received Rota (Rotarix lyophilized formulation) (batch number 5BC7N, expiry date 11th July 2022) for prophylaxis. Co-suspect products included rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis, DTPa-HBV-IPV (Pediarix) (batch number T4Y35, expiry date 28th November 2022) for prophylaxis and dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis. On 6th May 2021, the patient received Rotarix lyophilized formulation (oral), Rotarix Oral Applicator Device, Pediarix and Pediarix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Rotarix lyophilized formulation, Rotarix Oral Applicator Device, Pediarix and Pediarix Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The nurse reported about Pediarix and Rotarix administration to patient after the vaccines suffered a below temperature excursion, which led to incorrect storage of drug. No further events were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-